Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ETX-018810 · 2 trials · 3 indications
Change from baseline in the weekly average of the daily pain score as derived from the subject's responses on the Pain Intensity Numerical Rating Scale (PI-NRS), a 10 point scale from 0 being the least (No Pain) to 10 being the most (Worst Possible Pain).
| Arm | Type | Description |
|---|---|---|
| ETX-018810 | EXPERIMENTAL | Drug: ETX-018810 BID for 4 weeks |
| Placebo | PLACEBO_COMPARATOR | Matching Placebo BID for 4 weeks |
| Name | Type | Description |
|---|---|---|
| ETX-018810 | DRUG | Study Drug |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * The subject has pain consistent with a diagnosis of chronic lumbosacral radiculopathy due to injury of the lumbosacral nerve root(s) * The subject reports at least moderate pain intensity at screening. * The subject's onset of leg pain due to LSRP is at least 3 months * The su...
ETX-018810 is an investigational small molecule developed by Climb Bio, Inc. for neurologic pain conditions. It has been studied in Phase 2 clinical trials for diabetic peripheral neuropathic pain and lumbosacral radiculopathy, also called lumbosacral radicular pain. It is not described as approved and remains in clinical development.
ETX-018810 has been studied for two pain indications: diabetic peripheral neuropathic pain, a nerve pain condition associated with diabetes, and lumbosacral radiculopathy, which is pain radiating from the lower spine. Both were evaluated in Phase 2 trials conducted in the United States in adults aged 18 years and older.
ETX-018810 is being developed by Climb Bio, Inc., which trades under the ticker CLYM. The company is the sponsor of the clinical program evaluating the small molecule in neurologic pain indications, including diabetic peripheral neuropathic pain and lumbosacral radiculopathy.
ETX-018810 is in Phase 2 development. Its two Phase 2 trials, one in diabetic peripheral neuropathic pain and one in lumbosacral radicular pain, are both listed as completed. No Phase 3 program is described, so the asset remains an investigational drug rather than an approved therapy.
ETX-018810 has been evaluated in two completed Phase 2 trials. NCT04688671 tested it in diabetic peripheral neuropathic pain with 167 participants, and NCT04778592 tested it in lumbosacral radicular pain with 149 participants. Both were randomized, double-blind, placebo-controlled studies conducted in the United States.
Both Phase 2 trials of ETX-018810 were randomized, double-blind, and placebo-controlled, enrolling adults aged 18 years and older of any sex in the United States. NCT04688671 enrolled 167 participants with diabetic peripheral neuropathic pain, and NCT04778592 enrolled 149 participants with lumbosacral radicular pain. Both studies are completed.